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Abstract: Peptides are fragments of proteins that carry out biological functions. They act as signaling
entities via all domains of life and interfere with protein-protein interactions, which are indispensable in bio-processes. Short peptides include fundamental molecular information for a prelude to
the symphony of life. They have aroused considerable interest due to their unique features and

Molecules 2021, 26, 430. https://doi.org/10.3390/molecules26020430

https://www.mdpi.com/journal/molecules

Molecules 2021, 26, 430

2 of 45

great promise in innovative bio-therapies. This work focusing on the current state-of-the-art short
peptide-based therapeutical developments is the first global review written by researchers from all
continents, as a celebration of 100 years of peptide therapeutics since the commencement of insulin
therapy in the 1920s. Peptide “drugs” initially played only the role of hormone analogs to balance
disorders. Nowadays, they achieve numerous biomedical tasks, can cross membranes, or reach
intracellular targets. The role of peptides in bio-processes can hardly be mimicked by other chemical
substances. The article is divided into independent sections, which are related to either the progress
in short peptide-based theranostics or the problems posing challenge to bio-medicine. In particular,
the SWOT analysis of short peptides, their relevance in therapies of diverse diseases, improvements
in (bio)synthesis platforms, advanced nano-supramolecular technologies, aptamers, altered peptide
ligands and in silico methodologies to overcome peptide limitations, modern smart bio-functional
materials, vaccines, and drug/gene-targeted delivery systems are discussed.
Keywords: short peptides; constrained amino acids and peptide (bio)mimetics; drug design and
drug/gene delivery; vaccines; aptamers; cell-penetrating peptides; synthesis; SARS-COV-2; cancer;
bilayer interactions; altered peptide ligands; ant/super/agonists; diketopiperazine; cosmeceuticals

1. Introduction
2. Brief History
3. Short Peptides: Definition
4. Frontiers and Prospects of Short Peptides
4.1. Advantages vs. Disadvantages: SWOT Analysis
4.2. To Overcome Shortcomings of Peptides: Mission (Im)possible?
4.2.1. Constrained Amino-Acids as a Molecular “Meccano”
4.2.2. Cyclic Peptides and Mimetics
4.2.3. Ultra-Short Peptides: Less Is More
4.2.4. Nanoengineering & a Supramolecular Approach
5. Synthesis
5.1. Advances in the Synthesis of Short Peptides and Modified Amino Acids
5.2. Short Difficult Peptide Synthesis
6. In Silico Studies
6.1. Geometry Optimization, Conformational Analysis
6.2. Modelling of Short Peptides
6.3. Peptide Interactions with Lipid Bilayers using Molecular Dynamics Simulations
7. Peptide-Based Therapies
7.1. Monocyclic, Bicyclic and Tricyclic Cell-Penetrating Peptides as Molecular Transporters
7.2. Short Peptides in Gene Delivery
7.3. Taking Peptide Aptamers to a New Level
7.4. Peptide-Based Vaccines
7.5. The Role of Short Peptides in Neurodegenerative Therapy
7.6. Immune Modulation Using Altered Peptide Ligands in Autoimmune Diseases
7.7. Relevance of Short Peptides in Stem Cell Research
7.8. Short Peptide-Based Anti-Viral Agents against SARS-CoV-2
7.9. Antimicrobial Lactoferrin-Based Peptides as Anti-COVID-19
7.10. Peptides from Digestion of Proteins
7.11. Nutraceuticals
7.12. Marine Peptides
7.13. Peptide-Based Cosmeceuticals
1. Introduction
Recently, short peptides have attracted increasing attention in biology, chemistry,
and medicine due to their specific features. They are appreciated as novel and more
efficient therapeutical agents with reduced side effects. Their structural diversity combined
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with the conformational flexibility is used to control interactions with particular receptor
sites. Peptides display high selectivity due to specific interactions with their targets.
Moreover, the number of short peptides involved in important biological processes is
steadily growing by far exceeding that resulting from the traditional mimetic approach.
Unfortunately, peptides also have profound medical limitations, namely the development
of oral peptide-based therapeuticals that modulate cellular processes via high affinity
binding is like a search for the Holy Grail [1].
This critical review is written by a broad, multidisciplinary group of leading scientists, experts in the field from academia and pharmacy from all continents of the world
providing a priceless global point of view on short peptides towards biomedical innovations. It is compiled as a holistic story from very simple bio-molecules to next-generation
advanced theranostics in diverse, multidirectional scenarios. More specifically, the advantages vs. disadvantages of short peptides, their relevance in therapies of a wide range
of diseases, improvements in (bio)synthesis platforms, advanced nano-supramolecular
technologies, aptamers, altered peptide ligands and in silico methodologies to overcome
peptide limitations, modern smart bio-functional materials, vaccines, and drug/genetargeted delivery systems are considered. It gains unequaled insight into the world of
functional biologically active peptides either accessible from nature’s repertoire or synthetic species. Short peptides, as fragments of proteins, have become intriguing agents of
almost unlimited possibilities, which are awaiting further exploitation in the near future.
We profoundly believe that these simple bio-molecules will open up whole new vistas,
offering promising solutions in shaping the future novel bio-medicine.
2. Brief History
In 1902, two distinguished German chemists, Hermann Emil Fischer and Franz
Hofmeister, proposed that proteins are constituted by amino acids linked by bonds between
the amino group of the proceeding amino acid and the carboxyl group of the following
residue [2]. However, proteins were initially characterized by the Dutch chemist Gerardus Johannes Mulder, but their name was coined out by the Swedish chemist Jöns Jacob
Berzelius, in 1838 [3,4]. The term “protein” is derived from the “proteios” (“primary”)
i.e., representing the first position in living organisms [4–6]. Nevertheless, proteins do
not exist without peptides. A name “peptide” comes from “peptós” (in Greek “digested,
digestible”) and reflects the fact that peptides are generated by the proteolytic cleavage
reaction. The first peptides and amino acids were discovered at the beginning of 19th century [7,8]. The first amino acid, asparagine, was isolated from asparagus by French chemists
Louis-Nicolas Vauquelin and Pierre Jean Robiquet in 1806 [9,10]. Their chemical category
was recognized by the French Charles Adolphe Wurtz, in 1865, but the expression “amino
acid” was used for the first time in 1894, in German as Aminosäure [11,12]. Interestingly,
the first peptide, benzoylglycylglycine, was synthesized by the German chemist Theodor
Curtius, in 1881 [13]. However, a more efficient synthesis was described by Fischer and the
French chemist Ernest Fourneau in 1901 [14,15]. In consequence, Fisher is known as the
“father” of peptide chemistry [16].
Peptides exist in all terrestrial living organisms and are indivisibly related to the origin
of life [17]. Cooperative interactions among peptides and other molecules (amino acids,
proteins, nucleic acids, lipids) were the driving forces at all stages of chemical evolution [18].
Nowadays, a chemical peptide synthetic biology approach facilitates theories on the creation of life, in particular in the eyes of scientists who believe that historically chemistry
proceeds biology [19–21].
3. Short Peptides: Definition
In general, a peptide consists of at least two amino acids. An oligopeptide is a short
chain of amino acids (“a few”). A polypeptide is a long chain of amino acids (“many”).
Protein contains at least one polypeptide chain folded into correct shapes. There is no strict
boundary between a peptide and a protein or an oligopeptide and a polypeptide other than
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the “size”. As stated in the International Union of Pure and Applied Chemistry (IUPAC),
oligopeptides consist of fewer than about 10–20 amino acids, while polypeptides have
more than 20 residues [22]. According to the biological dictionary, oligopeptides comprise
about 2–40 amino acids, while the medical definition indicates a fragment of protein
consisting of fewer than 25 amino acids. On the other hand, proteins, according to IUPAC
can be polypeptides consisting of more than about 50 mers, but there are great differences
regarding the term protein. In the Britannica encyclopedia, we can read: “peptide chains
longer than a few dozen amino acids are called proteins” [23]. Typical proteins contain
over 100 amino acids [5,24]. The smallest natural mini-protein is crambin, consisting of
46 amino acids [25], while the largest protein is titin with 38,138 amino acid residues [26].
Hence, the determination of “short peptide” is problematic. It depends on the reference
point. The strict definition has not been given so far. Short peptides have features of
oligomers rather than polymers [5], but there is no clear consensus among scientists. In the
literature, we can find contradictory information, with fewer than 30 [27–29] or 50 [30–33],
up to 100 residues [34]. On the other hand, ultra-short peptides were precisely defined as
peptides consisting of up to seven amino acids [35–38].
In view of the above, we can conclude that oligopeptides are always only peptides,
while polypeptides can be proteins as well. Consequently, short peptides should not
include more than 45 amino acids.
4. Frontiers and Prospects of Short Peptides
4.1. Advantages vs. Disadvantages: SWOT Analysis
Peptides as a unique class of bio-molecules have filled the therapeutic niche due to
their specific biochemical and therapeutic features. They explore the “middle space” between small chemical molecules and biologics because of their molecular weight. They have
the intermediate nature extending “beyond size”, combining the advantages of both small
molecular drugs (e.g., better permeability) and therapeutic proteins (selectivity, target
potency) and exluding their disadvantages, such as adverse side effects, drug-drug interactions, and membrane impermeability, respectively.
Short peptides have evolved as a very promising scaffold for diverse applications either
in diagnosis or therapies. The current status of their strengths, weaknesses, opportunities and
threats (SWOT analysis) [39] is briefly discussed (Table 1).
Table 1. SWOT analysis of short peptides.
Strengths
essential bio-molecules with a broad range of activities &
functionalities in vivo

Weaknesses
instability in vivo (easy degradation in plasma,
protease sensitivity)

bio-chemical diversity, easy availability

short half-life

structural simplicity

low (oral) bioavailability

easy design & cost-effective synthesis with high purity

difficult membrane permeability in the case of greater peptides *

easy modification, scaling up

low binding affinity *

mechanical stability

high conformational freedom *

high: modularity, flexibility *, selectivity, target specificity,
affinity *, absorbability, potency, tolerability, efficacy, safety,
biocompatibility, biodegradibility
low toxicity, antigenicity, immunogenicity
easy recognition by bio-systems
ability to penetrate the cell membranes (but only very short
peptides) *, high brain penetration in systematical
administration
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Table 1. Cont.
Strengths

Weaknesses

versatility as both targeting moieties and therapeutic agents
specific interactions with various bio-systems
predictable metabolism: degradation products are amino acids
(non-toxic, natural entities used as nutrients or cellular
building blocks)
lack or fewer secondary off-targets (side) effects (peptides do
not accumulate in kidney or liver)
low unspecific binding to the structures other than the desired
target, minimisation of drug-drug interactions, less
accumulation in tissues (low risk of complications due to
intermediate metabolites)
Opportunities

Threats

development of peptide-based delivery systems:
- cell-penetrating peptides
- nano-cyclic peptide-based micceles, vesicles as gene or
drug carriers
- conjugations with non-peptidic motifs

oncogenicity of endogenous & synthetic peptides

supramolecular peptide-based biofunctional materials

immunogenicity (related to greater peptides)

formulations development (e.g., subcutaneous
injections)various forms of using (drugs, vaccines,
hormones, radioisotopes)
development of the peptide-based safe & effective vaccines
diveristy of well-ordered, robust, long-lived
self-assembled nanostructures
vital tool for neurodegenerative diseases studies & various
applications in anticancer therapy
peptoids or peptidomimetics
* Bivalent property which may be either strength or weakness depending on particular species.

First of all, short peptides have numerous advantages in comparison with their
larger analogues. In particular, cost-effective synthesis both on a small- and large-scale,
wide chemical diversity, easy modification, high bio-activity, absorbability, accessibility,
tunable functionalization, high selectivity and specificity, biodegradability and biocompatibility, high safety, low toxicity (due to their safe metabolites-amino acids, the limited possibility for accumulation in the body), or low immunogenicity should be emphasised [40].
Peptides have diverse bio-functionalities of their components (amino acids) and good
biomolecular recognition [34,41]. As a consequence, they have high binding affinity for a
wide range of specific targets.
On the other hand, short peptides have limitations, such as high conformational
flexibility (can result inter alia in the lack of receptor selectivity) or problems in permeability
of greater peptides via physicological barriers (due to the strong interactions of peptide
backbone with water molecules) [42]. Moreover, there are other important factors, e.g.,
short half-life in vivo (due to the susceptibility to rapid digestion by protolytic enzymes
in the gastrointestinal tract and serum, proteases/peptidases) and fast clearance from the
circulation (first-pass metabolism) by the liver and kidneys (lasting from minutes to hours
after administration). In spite of approvement of over 60 peptide drugs, nearly none can be
orally administrated [43]. Market placement of effective peptides as oral medications is
still the “Holy Grail”. Furthermore, the risk of immunogenic effects is the main threat of
peptide therapies [42].
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4.2. To Overcome Shortcomings of Peptides: Mission (Im)possible?
There are different approaches and strategies to overcome peptide limitations and
enhance their bio-clinical applications [44]. First and foremost, structural modifications
can lead to the improvement of physicochemical properties. Simple modifications result
in greater general stability. It can be additionally improved by “double-bridged peptides”
when peptides are cyclized via two chemical bridges. It reduces peptide backbone flexibility
and in consequence, leads to limited availability for enzymes. Furthermore, variations in
the sequence lenght and side chains, peptide backbone modification, C-terminal amidation, N-terminal acetylation, addition of stabilizing (sugars, salts, heparine) and chelating
agents, e.g., ethylenediaminetetraacetic acid (EDTA), conjugations with large biocompatible polymers, such as polyethylene glycol (PEG), or fatty acids can be applied. In this
way, we can stabilize peptides in their bioactive conformation, increase efficiency, hydrodynamic volume, and reduce renal clearanced and show greater membrane permeability
and target selectivity [33,41–45]. Furthermore, the conjugation to cell-penetrating peptides
(or organelle-targeting sequences) increases cellular membrane crossing and allows accessing intracellular targets by peptide-drugs or acts as gene delivery vectors revealing
great potential for clinical use as theranostics leading to better drug bioavailability and
therapeutic efficiency [46,47]. The conjugations of short peptides with non-peptidic motifs
enhance bioactivities: A promising strategy for the discovery of new drugs (improve peptide delivery and cellular uptake) [48]. Synthetic short peptides as accurate copies of
protein parts are ideal tools for imitation of protein sites [47]. Peptoids, which are based on
native peptides, can lead to the improved pharmacokinetic profile [49,50]. Novel methods
such as phage display can be used to develop short peptides, which can survive proteolytic
degradation in the gastrointestinal tract and can be used as therapeutical agents with high
affinity in inhibition of the coagulation Factor XIa or as antagonists for the interleukin-23
receptor in the chronic inflammatory Crohn‘s disease, ulcerative colitis [51]. They may be a
milestone towards engineering oral peptide drugs in the treatment of diseases affecting
billions of people worldwide [52,53].
4.2.1. Constrained Amino-Acids as a Molecular “Meccano”
Intensive efforts have been made to develop short peptides or peptidomimetics that
display more favourable pharmacological properties than their prototypes [54]. Most of
the research carried out in the field concern the preparation of analogues with different
chemical structure and possibly modified conformational preferences, responsible for inducing changes in the biological activity. Structural changes can be obtained in a peptide
by selectively substituting along the sequence specific residues with other residues or
by substituting certain residues of the sequence with non-coded α-amino acid residues.
Appropriate constrained non-coded α-amino acid residues are of particular interest as
“building blocks” for the preparation of analogs, since their inclusion in a peptide sequence could maintain the pharmacological properties of the native peptide and possibly
enhance resistance to biodegradation with improved bioavailability and pharmacokinetics.
Several solid-state studies have been carried out to define the conformational preferences
in solution and in the solid-state of specific classes of non-coded α,α -amino acids, for
example, the symmetrical and unsymmetrical α,α-disubstituted glycines (α,α-dialkylated
amino acid residues) (Figure 1) [55–66]. The structural preferences of peptides containing
non coded amino acid residue are unique with significant constraints of their conformational freedom. This point is particularly important for the use of these residues and their
analogues as scaffolding units in the de novo design of protein and enzyme mimetics and,
also, as templates for molecular and chiral recognition studies. More in general with this
knowledge we are able to rationally design new peptides relevant to pharmacology and
medicinal chemistry, which might mimic biological processes by enhancing or in general
modulating their effects. The peptide pharmaceutical targets of these studies have been
among others hormones, enzymes, transport systems, antibiotics, sweeteners, etc. [67–72].
Another important application of constrained amino acid is in the peptide self-assembly.
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importance. Furthermore, cyclizations were a way to define and lock the active conformation of the peptide. Structure–activity studies have shown the importance of the three
aromatic
amino
acids Tyr,
His, Phe, for
andactivity.
the C-terminal
for activity.
In order
Phe,
and the
C-terminal
carboxylate
In order carboxylate
for cyclic analogues
to retain
the
for cyclic
to retaincyclization
the activityshould
of the occur
linear at
peptide,
should
occur
at
activity
ofanalogues
the linear peptide,
residuecyclization
positions that
are the
least
residue positions
thatwith
are the
least important
for activity
with retention
theconformabioactive
important
for activity
retention
of the bioactive
conformation
[78–81].ofThe
tion
of peptides[78–81].
is deduced
modern Nuclear
Magnetic
Resonance
techniques,
such as
conformation
The from
conformation
of peptides
is deduced
from
modern Nuclear
two-dimensional
(2D)
NMR
ROESY,
NOESY,
COSY,
and
TOCSY
in
lipophilic
environments.
Magnetic Resonance techniques, such as two-dimensional (2D) NMR ROESY, NOESY,
Based
losartan,
andenvironments.
our ring cluster
and on
charge
relaysarmesin,
system conformation,
COSY,on
and
TOCSYsarmesin,
in lipophilic
Based
losartan,
and our ring
we
designed
and synethsized
angiotensin
II receptor
blockers and
by rotation
of theangiotensin
alkyl chain
cluster
and charge
relay system
conformation,
we designed
synethsized
on
the imidazole
ring.
rotation
resulted
in losartan
and BV6 ring.
derivatives
of similar
II receptor
blockers
byThis
rotation
of the
alkyl chain
on theV8
imidazole
This rotation
reactivity
losartan
The
perspectives
the use
of angiotensin
receptor
blockers
sulted inwith
losartan
V8 [91,92].
and BV6
derivatives
of in
similar
activity
with losartan
[91,92].
The
(ARB)
are huge.
ARB
and
enzyme(ARB)
(ACE)1
were
recently
perspectives
in the
use
of angiotensin-converting
angiotensin receptor blockers
areinhibitors
huge. ARB
and
angiofound
to
protect
hypertensive
patients
infected
from
Severe
Acute
Respiratory
Syndrome
tensin-converting enzyme (ACE)1 inhibitors were recently found to protect hypertensive
Coronavirus
(SARS-Cov-2)
[93].
The Respiratory
renin-angiotensin
system
(RAS) inhibitors
reduce
patients infected
from Severe
Acute
Syndrome
Coronavirus
(SARS-Cov-2)
the
II and increase
antagonist
heptapeptides
alamandine
and aspaman[93].toxic
Theangiotensin
renin-angiotensin
system (RAS)
inhibitors
reduce the
toxic angiotensin
II and
dine,
which
counterbalance
angiotensin
II and maintain
homeostasiswhich
and vasodilation
[94]
increase
antagonist
heptapeptides
alamandine
and aspamandine,
counterbalance
(Figure
2).
angiotensin II and maintain homeostasis and vasodilation [94] (Figure 2).

Figure 2. Angiotensin
AngiotensinII II
(Asp-Arg-Val-Tyr-Ile-His-Pro-Phe),
Losartan,
Losartan
analogues
(Asp-Arg-Val-Tyr-Ile-His-Pro-Phe),
Losartan,
V8 V8
Losartan
analogues
(R =
CH
2
OH,
COOH).
The
angiotensin
II
scheme
depicts
the
pharmacophoric
groups
of
the
eight
amino
(R = CH2 OH, COOH). The angiotensin II scheme depicts the pharmacophoric groups of the eight
acids ofacids
angiotensin
II.
amino
of angiotensin
II.

4.2.3.
Ultra-Short Peptides:
Less Is
Is More
More
4.2.3. Ultra-Short
Peptides: Less
Very
Very short
short peptides
peptides have
have outstanding
outstanding attributes,
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such as
as much
much easier
easier and
and economic
economic
synthesis,
higher mechanical
mechanicalstability,
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goodtissue
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andless
lessimmunogenicity
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ity
Overall,
the costs
of production
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the lenghth
the amino-acids
[42].[42].
Overall,
the costs
of production
increase
with with
the lenghth
of theof
amino-acids
chain.
chain.
In
addition,
a
complex
control
and
characterization
are
simpler.
Furthermore,
In addition, a complex control and characterization are simpler. Furthermore,
very short
very
shorthave
peptides
better tunability,
bio- and cytocompatibility
(non-hemoliticity
and
peptides
betterhave
tunability,
bio- and cytocompatibility
(non-hemoliticity
and non-cynon-cytotoxicity)
[95],
biodegradability,
and
non-immunogenicity,
in
comparison
with
their
totoxicity) [95], biodegradability, and non-immunogenicity, in comparison with their
longer
They can
can support
support the
the growth
growth of
of diverse
diverse cells
cells and
and their
their differentiation
differentiation [96].
[96].
longer analogs.
analogs. They
As
As aa result,
result, structural
structural optimization
optimization is
is easier.
easier. Ultra
Ultra short
short peptides
peptides are
are more
more amenable
amenable to
to
oral delivery. They contain necassary molecular information on spontaneous self-assemble
oral delivery. They contain necassary molecular information on spontaneous self-asseminto the ordered nanostructures [97]. Fluorenylmethoxycarbonyl(Fmoc)-diphenylalanine is
ble into the ordered nanostructures [97]. Fluorenylmethoxycarbonyl(Fmoc)-diphenylalaa good example of highly ordered peptide (hydrogel) with antimicrobial activity [98,99]
nine is a good example of highly ordered peptide (hydrogel) with antimicrobial activity
leading to the acceleration of wound healing [100]. Ultra-short nanoparticles can overcome
[98,99] leading to the acceleration of wound healing [100]. Ultra-short nanoparticles can
the drug problem related to low half-life. As an example, encapsulation of curcumin in
overcome the drug problem related to low half-life. As an example, encapsulation of curthe form of nanocarrier can be used in a “controllable release” way to repair brain tissues
cumin in the form of nanocarrier can be used in a “controllable release” way to repair
as a promising drug in neurodegenerative diseases [101]. Moreover, ultra-short peptides
brain tissues as a promising drug in neurodegenerative diseases [101]. Moreover, ultraare suitable for many bioapplications, innovative nano-theranostics (either therapeutic or
short peptides are suitable for many bioapplications, innovative nano-theranostics (either
diagnostic), especially in cancer cell growth inhibition, and advanced smart system fortherapeutic or diagnostic), especially in cancer cell growth inhibition, and advanced smart
mulations [102–106]. The latter include oral administration which increases drug efficacy
system formulations [102–106]. The latter include oral administration which increases
and safety.
drugThe
efficacy
and safety.
simplest
cyclo-peptides, also known as 2,5- (and 2,3- or 2,6-) diketopiperazines
The
simplest
cyclo-peptides,
also known as 2,52,3- oranhydrides,
2,6-) diketopiperazines
(DKP), piperazine-2,5-diones,
2,5-dioxopiperazines,
and(and
dipeptide
are another
(DKP),
piperazine-2,5-diones,
2,5-dioxopiperazines,
and
dipeptide
animportant issue. They have amazing advantages in drug discoveryanhydrides,
due to theirare
extra
other important
issue.
They have
amazing
advantages in drug
discovery
due to their[107],
extra
features,
inter alia
superior
rigidity,
three-dimensionality,
higher
cell permeability
features,
inter
alia
superior
rigidity,
three-dimensionality,
higher
cell
permeability
[107],
and diverse bio-activities: Anticancer, antiviral, antioxidant, in neurodegeneration prevention, quorum sensing, cell-cell signaling, as drug delivery systems (e.g., in connection with
cell-penetrating peptides) and so on [108–110]. DKPs are widespread in nature. They occur either in the marine and terrestrial environment, in microorganisms or high species,

Molecules 2021, 26, x FOR PEER REVIEW

Molecules 2021, 26, 430

9 of 45

and diverse bio-activities: Anticancer, antiviral, antioxidant, in neurodegeneration9 of
pre45
vention, quorum sensing, cell-cell signaling, as drug delivery systems (e.g., in connection
with cell-penetrating peptides) and so on [108–110]. DKPs are widespread in nature. They
occur either in the marine and terrestrial environment, in microorganisms or high species,
or
food and
and drugs
drugs [111,112].
[111,112]. InInthe
thelatter
lattercase,
case,DKPs
DKPsare
areinner
inner
cyclization
products
or in
in food
cyclization
products
of
of
bio-active
substances,
e.g.,
ACE
inhibitors
[113–122].
Noteworthily,
they
have
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as corresponding
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They were
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nervous
system,
gastrointestinal
tract,
and
blood
[123].
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nervous system, gastrointestinal tract, and blood [123]. Interestingly, they played a key
arole
keyinrole
the origin
life [112,124].
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interest
in simplest
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thein
origin
of lifeof
[112,124].
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interest
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naturalnatural
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is noticeable
due
to their
potential
in future
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2,5-DKPs
peptides is noticeable
due to
their
hugehuge
potential
in future
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2,5-DKPs
are are
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in
almost
50
bio-complexes
deposited
in
the
Research
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for
Structural
served in almost 50 bio-complexes deposited in the Research Collaboratory for Structural
Bioinformatics
Bioinformatics Protein
Protein Data
Data Bank
Bank (RCSB
(RCSB PDB)
PDB) [125]
[125] (Figure
(Figure 3).
3).

Figure 3.
3. Bio-complex
Bio-complex containg
containg 2,5-DKP
2,5-DKP moiety
moiety [1O6I.pdb].
[1O6I.pdb].
Figure

Generallyspeaking,
speaking,short
short
peptides
gaining
more
popularity.
ExploraGenerally
peptides
areare
gaining
more
and and
moremore
popularity.
Exploration
of
tion of
their
new modifications
seems promising
for new advanced
research
be
their
new
modifications
seems promising
for new advanced
research and
will beand
the will
key to
the key to innovative
smart bio-medical
applications
[126].
innovative
smart bio-medical
applications
[126].
4.2.4.
4.2.4. Nanoengineering
Nanoengineering and
and aa Supramolecular
Supramolecular Approach
Approach
Supramolecular
chemistry
(“chemistry
beyond
the molecule’’)
molecule”) is
Supramolecular chemistry (‘‘chemistry beyond the
is aa bottom-up
bottom-up apapproach
proach to
to the
the formation
formation of
of well-ordered
well-ordered structures
structures in
in the
the nanonano- (and
(and the
the micro-)
micro-) scale.
scale.
Their
Their adaptable,
adaptable, controllable,
controllable, self-healing,
self-healing, and
andbio-physico-chemical
bio-physico-chemical stimuli-responsive
stimuli-responsive
properties
induced
via
non-covalent
interactions
(electrostatic,
hydrogen
bonding,bonding,
π–π stacking,
properties induced via non-covalent interactions (electrostatic,
hydrogen
π–π
van
der
Waals
or
hydrophobic)
are
highly
appreciated
[123,127–132].
They
have
thehave
dystacking, van der Waals or hydrophobic) are highly appreciated [123,127–132].
They
namic
nature
and
provide
a
firm
basis
for
the
structure
and
functioning
of
living
systems.
the dynamic nature and provide a firm basis for the structure and functioning of living
Notably,
are controlled
by a plethora
of supramolecular
interactions.
The forsystems. bio-systems
Notably, bio-systems
are controlled
by a plethora
of supramolecular
interactions.
mation
of
deoxyribonucleic
acid
(DNA)
double
helix
via
H-bonding
interactions
between
The formation of deoxyribonucleic acid (DNA) double helix via H-bonding interactions
the
nucleo-bases
or the folding
proteins
tertiary
quaternary
structuresstructures
is a good
between
the nucleo-bases
or theoffolding
ofinto
proteins
intoand
tertiary
and quaternary
example
of
supramolecular
assemblies.
The
self-assembly
is
a
spontaneous,
reversible,
is a good example of supramolecular assemblies. The self-assembly is a spontaneous, reand ubiquitous process [98,127]. Self-assembling peptides are favorable platforms for the
versible, and ubiquitous process [98,127]. Self-assembling peptides are favorable platdevelopment of next-generation smart therapies. Minor structural changes can facilitate
forms for the development of next-generation smart therapies. Minor structural changes
the generation of new assemblies. Modified peptides with aromatic amino acids or funccan facilitate the generation of new assemblies. Modified peptides with aromatic amino
tionalized side chains (e.g., Fmoc) promote additional stacking interactions (Figure 4),
acids or functionalized side chains (e.g., Fmoc) promote additional stacking interactions
which are helpful in the self-assembly process. Peptide-based bio-functional supramolec(Figure 4), which are helpful in the self-assembly process. Peptide-based bio-functional
ular materials (nanomedicines, hydrogels, drug delivery vehicles, gene or drug carriers,
supramolecular materials (nanomedicines, hydrogels, drug delivery vehicles, gene or
biomimetic-cell culture scaffolds, tissue-engineering systems, biosensors, emulsifiers, pepdrug carriers, biomimetic-cell culture scaffolds, tissue-engineering systems, biosensors,
tidomimetic antibiotics, bioimaging nanoprobes, three-dimensional (3D) bioprinting inks,
emulsifiers, peptidomimetic antibiotics, bioimaging nanoprobes, three-dimensional (3D)
vaccine adjuvants) have low toxicity and high biocompatibility and are useful in various
bioprinting inks, vaccine adjuvants) have low toxicity and high biocompatibility and are
applications, like drug delivery, tissue engineering, immunology, cancer therapy, and stem
useful
in various
applications, like
drug delivery,
tissue engineering,
immunology,
cancer
cell
culture
[38,95,101,131–136].
Supramolecular
nanotherapeutics
have
better stability
and
therapy,
and
stem
cell
culture
[38,95,101,131–136].
Supramolecular
nanotherapeutics
have
efficacy, which helps to overcome problems related to peptide poor biostability and short
better stability
efficacy, which
helps to overcome
problems
related topeptides
peptide is
poor
plasma
half-life.and
Nanoparticles’
conjungtion
with inter alia
tumor-homing
an
biostability
and short
plasma half-life.therapy
Nanoparticles’
with
alia tumorattractive
avenue
for tumor-targeted
[136,137].conjungtion
The advances
ininter
the synthesis
of
supra-molecular assemblies prompt the development of theranostics (which possess specific smart features, such as programmability, multifunctionality, sensitivity, precise selectivity, biosafety) and are promising agents for personalized, smart medicine [126,138,139].
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5.1. Advances in the Synthesis of Short Peptides and Modified Amino Acids
5.1. Advances in the Synthesis of Short Peptides and Modified Amino Acids
The synthesis of modified amino acids and short peptides is based on reactions
The synthesis of modified amino acids and short peptides is based on reactions of
of functional groups. An example of modified amino acids at α-carbon atom could be
functional groups. An example of modified amino acids at α-carbon atom could be αα-hydroxymethylvaline [128], while 4-aminopyroglutamic acid can serve as cyclized dipephydroxymethylvaline
[128], while 4-aminopyroglutamic acid can serve as cyclized dipeptide
unit [140].
tide unit
The [140].
typical chemical peptide synthesis requires the condensation reaction of the cartypical
chemical
requires
theanother.
condensation
reaction
of the carboxylThe
group
of one
amino peptide
acid withsynthesis
the amino
group of
The only
two approaches
boxyl
group
of
one
amino
acid
with
the
amino
group
of
another.
The
only
two
approaches
to a peptide synthesis are the synthesis in solution and the solid-phase synthesis (SPPS).
to each
a peptide
synthesis
are the
synthesis
in solution
and theand/or
solid-phase
synthesis
(SPPS).
In
of them,
other steps
besides
peptide
bond formation
deprotection,
like
introIn each of
steps besides
peptide bond
formationThe
and/or
deprotection,
like induction
of them,
main- other
and side-chain
modifications,
are available.
liquid-phase
approach
is
troduction
of
mainand
side-chain
modifications,
are
available.
The
liquid-phase
apnow used mostly for the synthesis of short peptides up to tetrapeptide. During solid-phase
proach issynthesis,
now usedeach
mostly
for the
peptides uportoside
tetrapeptide.
During
peptide
peptide
is synthesis
anchoredof
atshort
the C-terminus
chain functional
solid-phase
peptide
synthesis,
each
peptide
is
anchored
at
the
C-terminus
or
side
group to an insoluble/soluble polymer. In both cases, a single N-protected amino acidchain
unit
functional
group
to an
insoluble/soluble
polymer.
In bothpeptides.
cases, a After
singledeprotection,
N-protected
is
coupled to
the free
N-terminal
amino group
of growing
amino reveals
acid unit
is coupled
the free
N-terminal
group
of growing
peptides.
After
which
a new
aminoto
group,
another
aminoamino
acid may
be attached.
Once
synthesis
is
deprotection,
which reveals
amino
group,
another
aminothis
acid
may bestep
attached.
complete,
the desired
peptidea isnew
cleaved
from
the resin.
Usually,
cleavage
is perOnce synthesis
is of
complete,
the desired
is cleaved
from could
the resin.
Usually,
this
formed
with acids
varying strength.
Anypeptide
functionalized
polymer
be used
as a solid
cleavage
step
is
performed
with
acids
of
varying
strength.
Any
functionalized
polymer
support, like for instance styrene cross-linked with 1–2% divinylbenzene [141], which is a
could becarrier
used as
a solid
support,
like
for instance
styrene
cross-linked
with 1–2% divipopular
resin
in SPPS.
Other
common
gel-type
supports
include polyacrylamide
nylbenzene
[141], glycol
which(PEG).
is a popular carrier resin in SPPS. Other common gel-type supand
polyethylene
portsIn
include
polyacrylamide
and polyethylene
glycolprecise
(PEG). product purification using
solution
peptide synthesis,
each step requires
In solution peptide
synthesis, eachIn
step
requires
product purification
using
gel chromatography
or crystallization.
contrast,
in precise
SPPS purification
is performed
as
gel
chromatography
In contrast,
in SPPS This
purification
is design
performed
as a
a
simple
washing of or
thecrystallization.
peptide attached
to the polymer.
allows to
peptide
synthesizers
andofautomate
the attached
synthetictoprocedure.
simple washing
the peptide
the polymer. This allows to design peptide synThe
most
commonly
used
peptide
coupling
thesizers and automate the synthetic procedure. reagents can be divided into two classes:
OlderThe
reagents—carbodiimides
and newer—salts
of 1-hydroxy-benzotriazole
and
most commonly used peptide
coupling reagents
can be divided into (HOBt)
two classes:
its
derivatives.
A danger of racemization
during carbodiimide
activation can(HOBt)
be circumOlder
reagents—carbodiimides
and newer—salts
of 1-hydroxy-benzotriazole
and
vented through the addition of ‘racemization suppressing’ additives such as triazoles
(HOBt) and its derivatives (for example 6-Cl-HOBt) or 1-hydroxy-7-aza-benzotriazole
(HOAt). A more recently developed additive for carbodiimide coupling with comparable
coupling efficiency to HOAt is ethyl cyanohydroxyiminoacetate (Oxyma) [142]. As newer
and commonly used reagents, there are compounds contained in the structure HOBt
(HBTU/TBTU/PyBOP), HOAt (HATU), 6-ClHOBt (HCTU). Their iminium, uronium,
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or phosphonium salt of a non-nucleophilic anion (tetrafluoroborate or hexafluorophosphate) act as coupling reagent with the ability of lowering racemization process [143].
The amino acids have to be orthogonally protected during any chemical reaction,
because of the presence of two or more reactive centers. In typical peptide synthesis,
orthogonal but permanent protection is necessary for the amino acids’side-chain functionalities. Another class of protecting group is required for temporary protection of the
α-amino group. The temporary protecting group is being cleaved repeatedly while the
permanent protecting groups have to withstand N-deprotection conditions. When the
synthesis is complete, they can be removed from the final peptide separately or simultaneously. Two principle orthogonal protecting group schemes are utilized in solution and/or
solid phase synthesis: So-called Boc/Bzl (tert-butyloxycarbonyl/benzyl) and Fmoc/t-Bu
(fluorenylmethylenoxycarbonyl/tert-butyl) approaches [144]. The Boc/Bzl-strategy requires side chain protecting groups, which should be stable during repetitive trifluoroacetic
acid treatment. SPPS can be automated far more conveniently for Fmoc/tert-butyl (tBu)
than for Boc/Bzl strategy. The advantage of Fmoc is that it is cleaved under very mildly
basic conditions, but it remains stable under acidic conditions. This allows the use of mild
acid-labile protecting groups, such as Boc and tBu groups, to be used on the side-chains of
amino acid residues of the target peptide. Among other protecting groups recommended
for special cases are for example allyloxycarbonyl (Alloc) for amino group and allyl ester for
carboxyl group. There is always the possibility for their selective removal in the presence
of Fmoc/tBu protections.
Solution phase synthesis as well as polymer supported synthesis can be utilized for
the modification of amino acids and/or amide bonds. Nowadays, among popular modifications are all kinds of cyclization. Peptides can be cyclized on a solid support and/or
in a solution with any coupling reagent. The disadvantage of the solution phase cyclization is a substrate high dilution necessity to limit the possible reactions to intramolecular
one. The solid-phase synthesis of head-to-tail cyclic peptides is not limited to attachment
through Asp, Glu, or Lys side chains. For example, cysteine has very reactive sulfhydryl
group, which can be utilized as an anchoring point.
5.2. Short Difficult Peptide Synthesis
Although many peptides are routinely synthesized by SPPS, a certain kind of peptides
is still difficult to be prepared. Such peptides are called “difficult sequence-containing
peptides” [145]; even pentapeptides such as Ac-Val-Val-Ser-Val-Val-NH2 are known as
an example. During the chain elongation, intra-/inter-molecular hydrophobic interactions and/or hydrogen bondings cause aggregation of protected peptides on the resin
to induce incomplete coupling and deprotection. Furthermore, after final deprotection,
hydrophobic peptides hamper HPLC purifications using H2 O-MeCN system. Modifying the
main chain amide bond by e.g., pseudoproline (ΨPro) method [146] or O-acyl isopeptide
method [147–149] often solves such problems. In these methods, main chain amide causing
the undesired secondary structures is protected or modified to improve SPPS efficiency.
For example, diabetes mellitus-related amylin is difficult to be prepared by the traditional
Fmoc SPPS but was synthesized successfully with the aid of ΨPro structure [150,151].
In the ΨPro method (Figure 5), side chain of Ser/Thr/Cys in the difficult peptide is protected as Pro-mimicking “ΨPro” during SPPS and final trifluoroacetic acid (TFA) treatment
liberates native Ser/Thr/Cys. Because N-alkylated amide cannot become a hydrogen
bond donor and N-alkylation of the amide bond affects the cis/trans ratio of the amide
bond, this modification drastically changes secondary structure of the growing protected
peptide on the resin [152,153]. The ΨPro method successfully applied to the synthesis of
short cyclic peptides as well [154,155]. As described above, during TFA-mediated final
deprotection reaction, the native peptide is released. This tracelessness is a strong point but
sometimes becomes a weak point; if the native peptide is hydrophobic, the following highperformance liquid chromatography (HPLC) purification would be difficult. To overcome
it, the O-acyl isopeptide method was developed (Figure 6). In this method, the target pep-
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ture (i.e., RT(310K) = 0.616 kcal/mole) exceeds the limits of modern force fields [181,182].
The structure obtained by energy minimization, however, is not necessarily the most stable
conformation. Energy minimization will stop when it reaches the first stable conformation,
and it usually encounters a local energy minimum. The minimization program has no
manner to identify that there is a more stable conformation and converge the optimization process to a global minimum. To identify the most stable conformation of peptide
it is necessary to generate different conformations and compare their energies. There are
two methods of doing this, using molecular dynamics and/or stepwise rotation of bonds
(conformational searching). Conformational searching is feasible for small oligopeptides
only. When the number of rotatable bonds exceeds 5, the entire conformational space
of a molecule can become extremely large. In recent years, the methods of molecular
dynamics were increasingly used to gain insight into the structure/function relationships
in short peptides and proteins [183–187]. One of the key questions to be answered when
checking the applicability of molecular dynamic simulations for peptides and/or proteins
is the extent to which the simulations appropriately sample the conformational space of
these molecules. If a given property is poorly sampled over the molecular dynamics (MD)
simulations, the results obtained have limited usefulness [184]. To improve the sampling
efficiency, new techniques were developed [184,185,187]. All-atom molecular dynamic
simulations can predict structures of peptides and other peptide foldamers with accuracy
of experiments [187,188]. Thus, MD simulations are a useful tool for prediction and/or
reproduction of experimental 3D structures of small proteins.
6.2. Modelling of Short Peptides
The growing interest in peptide research results from recent successes in designing
peptide sequences of therapeutic value. At present, more than 60 peptide drugs have
been approved for use, with hundreds being in clinical trials. A number of new methodologies, both experimental and in silico, have been developed to design active peptide
sequences and analyze peptide-protein interactions. The above-mentioned issues are discussed in a recent comprehensive review [44]. Here, we concentrate on the problems
encountered both on modelling as well as practical sides. From the theoretical point of
view, they result mainly from the intermediate size of peptides—neither relatively exact
calculations for small molecules, nor very approximate but often successful methodologies
used for protein-protein recognition, work properly for them. This is because the size and
flexibility of peptides are prohibitive for exact calculations on the one hand, excluding
the error-compensation mechanism, which we benefit from in addressing protein-protein
recognition problems on the other. The practical biological problem results from many
roles short peptides play in the living cells, many of which are not understood properly
until now. It may happen that the designed peptide is either: The (folding) inhibitor of the
essential protein or protein-protein (interaction) or protein function inhibitor also interacting with a different protein that it was designed to bind to; executes a biological function
for reason which is not meant or understood. There are numerous examples of these
effects, e.g., the peptide corresponding to the (83–93) segment of human immunodeficiency
virus (HIV) protease interferes with the formation of the (post-critical) folding nucleus
and inhibits folding of the protein [189], and native interface peptide fragments can be
used as proton-pump inhibitors inhibitors (PPI). It is reasonable to assume that protein
degradation products can affect PPIs in a similar manner [190], whereby short peptides can
affect cellular processes in a way beyond explanation at the current state at knowledge e.g.
there are more than 1700 peptides (sometimes fragments of angiotensinogen) known to
lower arterial hypertension [191]—the mechanism of their action is unknown. In addition,
our limited experience in targeting PPIs with peptides in bacterial cells for therapeutic
purposes [189] shows that a significant fraction (~20%) of designed peptides is deadly for
unknown reason.
In conclusion, interactions of peptides (both native and designed) are of great importance for the metabolic processes of the living cells. Their full understanding requires
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Figure 7. Representative snapshot of cationic peptides (red) adsorved into POPG (green)/POPE (blue) surfaces.
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(blue) surfaces.
Simulations were carried out using: (A) All atom model of Lipid bilayers and (B)

Coarse grain model of vesicles. Water and ion sites were removed for visualization purposes.

What we can get from simulations of peptide interaction with lipid bilayers?
Using MD simulation at the atomistic and CG levels could bring very valuable information on the short peptide-membrane interaction. We mention here the issues and
consider that this type of methodology has its contributions and challenges.
6.3.1. Peptide Affinity Dependency on Membrane Composition
The partition and insertion of single peptides in membrane of different composition have been broadly investigated using unbiased MD simulations at both description
levels, with very successful results [197]. Within this technique, it is possible to access
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to the molecular details and identify specific interactions (hydrogen bond, salt bridge,
cation π), peptide conformation, as well as bilayers properties associated with the interaction (induced defects with a variety of morphologies, stiffness, fluidity, etc.).
6.3.2. Free Energy Calculations through a Peptide Reaction Path
Important information could be obtained by calculating, for instance, the free energy
through a given path for the peptide translocation along the bilayer. For bilayers, the natural
path is the z direction (normal to the bilayer). The use of enhancement of the sampling
of configurational space is well established where we can highlight that several methods
such as umbrella sampling [198], adaptive biasing force (ABF) method [199], the WangLandau algorithm [200], steer molecular dynamics [201], and metadynamics have been
proposed [202].
6.3.3. Cooperative Effects
Among the proposed mechanisms of lithic action of peptides in membranes is the
formation of pores. The study of cooperative effects, such as a pore formation, is not an
easy task. It is hard to access with enhanced MD techniques or applying an electric field.
Combining CG [203] and atomistic [204] level MD simulations could be used to broadly
sample the phase space. Thus, different initial conditions could help to explore this space.
For instance, pre-assembled pores embbebed in lipid bilayers could bring information on
their stability dependence with the bilayer lipid composition [204].
7. Peptide-Based Therapies
7.1. Monocyclic, Bicyclic and Tricyclic Cell-Penetrating Peptides as Molecular Transporters
CPPs have become a subject of major interest [205,206] for the intracellular delivery of
therapeutic agents because of the limitations associated with linear CPPs, such as endosomal entrapment, toxicity, poor cell specificity [207], poor stability and degradation [208],
and suboptimal cell penetration. Several cyclic CPPs possess enhanced cell-penetrating
ability and improved physicochemical properties and proteolytic stability. Some cyclic
CPPs exhibit endosomal-independent uptake [209]. A few cyclic CPPs have been reported
to have a nuclear-targeting property [209]. We have summarized below some of the monocyclic, bicyclic, and tricyclic CPPs containing arginine and other amino acids (Figure 8).
We have reported the application of cyclic CPPs containing alternatively positively charged
arginine and hydrophobic tryptophan residues, [WR]4 and [WR]5 , as drug delivery tools
and nuclear targeting tools in 2011 [209]. Several other monocyclic CPPs were engineered
based on this template and were shown to be efficient molecular transporters for enhancing
the efficacy of existing chemotherapeutic, antiviral, and antibacterial agents [210–219].
The monocyclic CPPs containing tryptophan and arginine residues were also used to conjugate with potential therapeutic agents. For instance, monocyclic peptides were conjugated
with doxorubicin, paclitaxel, and camptothecin [216,220] demonstrating localization of the
drug moiety in the nucleus in case of doxorubicin. Adding to the previous work, we also
demonstrated that several monocyclic peptides containing cysteine and arginine residues,
such as cyclic [CR]4 , significantly enhanced the cellular uptake of a cell-impermeable phosphopeptide (F’)-Gly-(pTyr)-Glu-Glu-Ile (F’-GpYEEI) in the presence of endocytic inhibitors
and sodium azide in the lymphoblastic leukemia cell line (CCRF-CEM) [218]. Furthermore,
tryptophan and histidine-containing cyclic decapeptides [WH]5 demonstrated an increase
of the intracellular delivery of a cell-impermeable phosphopeptide and an anti-HIV drug,
emtricitabine [217]. In another effort, monocyclic [HR]4 peptides were used as a molecular
transporter and were able to double the permeability of F’-GpYEEI in human ovarian
adenocarcinoma cells (SK-OV-3) cells [214]. Two bicyclic peptides containing tryptophan and arginine residues, namely [W5 G]-(triazole)-[KR5 ] and FAM-[W5 E]-(β-Ala)-[KR5 ],
significantly enhanced the cellular delivery of cell-impermeable F´-GpYEEI in SK-OV-3.
The confocal microscopy exhibited that the peptides were localized in the nucleus and
cytosol [219]. Recently, we designed a tricyclic peptide [WR]4 -[WR]4 -WR]4 containing
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7.2. Short Peptides in Gene Delivery
7.2. Short Peptides in Gene Delivery
A variety of oligopeptides have been proposed to overcome the extracellular and inA variety of oligopeptides have been proposed to overcome the extracellular and
tracellular barriers in gene delivery. Peptide sequences can be incorporated in a complex
intracellular barriers in gene delivery. Peptide sequences can be incorporated in a complex
gene delivery system (GDS) or used alone as a single carrier. Short peptides can be comgene delivery system (GDS) or used alone as a single carrier. Short peptides can be
bined as constructs such as peptide dendrimers and potentially provide more than one
combined as constructs such as peptide dendrimers and potentially provide more than one
feature in a single system. Peptides used in gene delivery can be categorized as (1) targetfeature in a single system. Peptides used in gene delivery can be categorized as (1) targeting
ing peptides, (2) cell penetrating peptides, (3) endosome disruptive peptides, and (4) nupeptides, (2) cell penetrating peptides, (3) endosome disruptive peptides, and (4) nuclear
clear localization peptides.
localization peptides.
7.2.1. Targeting Peptides in GDSs
Small peptide sequences have extensive applications as targeting moieties on the
surface of GDSs. Conventional IgG antibodies (~150 kDa) are difficult and expensive
to produce and introduce a high chance of immunogenicity. In contrast, small targeting
moieties such as short peptides provide lower chance of immunogenicity due to lack
of Fc region, increased ligand multivalency, and easy production by peptide synthesis
methods [222–224]. Techniques such as phage display provides a means for identifying
specific peptide sequences able to target selective tissues or cells [225,226]. A variety
of peptides can be used either to target cell surface markers or subcellular elements
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in vivo. One of the most investigated target receptors on the cells, especially for cancer gene therapy are integrins, which are a class of cell adhesion molecules consisting
of an α and a β subunit. Targeting moieties against αv β3 integrin, highly expressed on
activated endothelial cells, contain a conserved arginine-glycine-aspartic acid (RGD) motif [227–231]. To achieve enhanced biological and pharmacokinetic properties, researchers
have designed different RGD-containing peptide analogs and clustered RGDs [232,233].
Targeting ligands against other cell surface markers such as growth factor receptors (GFRs),
transferrin receptors (TFRs), low density lipoprotein receptors (LRPs), acetylcholine receptors (AchRs), leptin receptors (LRs), and insulin receptors have been also investigated
in targeted GDSs [234]. An important design factor in decorating GDSs with targeting
peptides is accessibility of targeting moiety to interact with the target molecules effectively.
Hindrance of the short peptide inside the GDS with loose interactions such as electrostatic interactions could lead to reduced targeting efficiency [235]. Other than cell surface,
oligopeptides can be used to target the subcellular compartments such as endoplasmic
reticulum, mitochondria, or Golgi apparatus. General nanoparticle targeting approaches
to intercellular pathway/compartments can be found elsewhere [236–239].
7.2.2. Cell Penetrating Peptides in GDSs
Cell penetrating peptides (CPPs) are capable of translocating cargo therapeutics across
the plasma membrane [240]. Physicochemical nature of CPPs can be cationic, amphipathic, or hydrophobic. Cationic CPPs are generally composed of short sequences of
arginine or lysine. Some well-known examples are truncated Tat peptide (GRKKRRQRRRPPQ) [241], penetratin (RQIKIWFQNRRMK-WKK) [242], transportan 10 (AGYLLGKINLKALAALAKKIL) [243], and KALA (WEAK-LAKALAKALAKHLAKALAKALKACEA) [244].
Tat is a peptide fragment from residues 48 to 60 of the original transcription activating
factor of human immunodeficiency virus (HIV-1) [241] and penetratin is obtained from a
Drosophila homeodomain protein [242]. Tat-modified GDSs have shown enhanced cargo
transport across several biological membranes such as cellular, endosomal, and nuclear
membranes [245–248]. For peptides such as penetratin, the non-electrostatic interaction to
the non-polar parts of plasma membrane is also of great importance [249–251]. The number
of cationic residues, spacing between them, and inclusion of non-peptide elements such
as hydrophobic lipid moieties were discussed as important factors in designing optimal
synthetic CPPs [252–256].
7.2.3. Endosome-Disruptive Peptides in GDSs
Endosome-disruptive peptides destabilize the endosomal membrane leading to cargo
release into the cytosol. Some provide membrane fusogenic features either pH-dependent
or pH-independent. Sequences derived from the N-terminus of the influenza virus hemagglutinin HA-2 are hemolytic at pH 4, but not at pH 7 [257,258]. Protonation of the peptide acidic residues under acidic condition of endosomes would induce conformational
changes leading to membrane binding and destabilization [258,259]. On the other hand,
the hemolytic activity of melittin sequence is not pH-dependent [260,261]. MT20, a short
peptide consisting of the first 20 residues of melittin, was designed to increase hemolytic
activity at acidic pH and lower it at neutral pH [262]. Histidine-rich peptides are considered as another effective endosomolytic elements in GDSs. The imidazole ring in
Histidine structure acts as a weak base that can be protonated at pH 6 of endosomal compartment [263,264]. The pH-dependent protonation of histidine and histidine-containing
peptides result in pH-buffering as well as fusogenic capabilities linked with membrane disruptive effects [265–268]. Branched histidine-rich sequences have provided high gene and
siRNA transfection efficiencies [269,270]. Additional improvements were also observed
in cases in which polymeric gene carriers were modified with imidazole- or histidine-rich
sequences [265,271–273]. Amphipathic sequences such as the peptide, which consists of a
tandem repeat of glutamic acid–alanine–leucine–alanine (GALA), was also employed in
GDSs to provide pH-sensitive fusogenic feature in acidic pH [274,275].
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7.2.4. Nuclear Localization Peptides in GDSs
Nuclear localization signals (NLSs) are reported to transfer cargos such as nucleic
acids through the nuclear pore complex (NPC) of non-dividing or slowly dividing cells.
They are believed to act as adaptors between the cargo and the importin-dependent
nuclear transfer machinery. Short NLSs such as monopartite SV40 large T antigen with the
sequence of PKKKRKV [274], or bipartite nucleoplasmin with the sequence KRPAATKKAGQAKKKK [276], have been reported to provide enhanced DNA transfection efficiency [277].
Peptides derived from H1 histones, protamines, ribonucleoprotein A1, and high motility
group (HMG) proteins could also direct DNA to the nucleus [278,279]. NLSs have been
extensively used to modify GDSs for improved transfection capability [280,281]. Due to
the cationic nature of most of these peptides, some believe that the enhanced gene delivery
efficiency observed with them, may be related to factors other than effective nuclear
recognition [282], including better polyplex morphology and DNA binding strength.
7.3. Taking Peptide Aptamers to a New Level
Aptamers are molecules whose structures have been conformed to adapt to a target
ligand in such a way as to optimise binding interactions between the aptamer and that
ligand. Aptus in Latin means attached, adjusted. They can be constructed from a range of
diverse chemical species and while nucleic acids are some of the first templates to have
been employed for this approach, peptide aptamers are attracting increasing attention because of their biocompatibility, wide variety of physical characteristics, ability to introduce
modifications using standard chemical techniques, and ease of large-scale manufacture.
In this review, the different methods employed for designing peptide aptamers are discussed, together with new methodologies that can extend yet further their huge potential.
Peptide aptamers can be broadly defined as peptides that have been adapted to interact
with a specific target, usually employing a methodology that is able to select out high
binders from a combinatorial library. Like nucleotide aptamers, the methods used to date to
generate peptide aptamers have relied on genetic amplification mechanisms. The archetype
of this approach is phage display [283]. Starting with a library of randomly generated
amino acid sequences spliced into large scaffold proteins, in this case coat proteins of a
bacteriophage, those phages that bind to a target can be separated from non-binders and
those grown up in host cells to harvest those sequences with the strongest interaction.
The power of the technique is that every individual sequence has, physically associated
with it, the nucleic acid strand that codes for it, so that separating out the binding peptide
separates out the coding nucleic acid at the same time. The same principle applies to all
other methodologies employed so far.
Instead of being expressed on the phage surface, the library can be expressed on
the surface of the bacteria growing the phage [284], or can be simplified to a cell-free
presentation system where modifications made to the coding RNA (removal of the stop
codon) result in a ribosomal complex in which mRNA, ribosome, and nascent protein
remain physically attached to each other [285]. Extensions of this approach give rise to
more stable protein-RNA conjugates in which the ribosome departs the complex after
chemical ligation transfers the RNA directly to the protein [286].
At the same time, the technique has also progressed in the other direction, so that the
aptamer target binding interaction actually takes place inside the cell that generates the
aptamer [287], allowing for a more diverse set of read-outs than simply binding interactions.
Many different scaffold proteins are employed, chosen for their stability and their
ability to accommodate stretches of foreign sequences while still folding into a single,
unequivocal tertiary configuration. Certain scaffolds are more appropriate for hosting
binding epitopes in the form of clefts (e.g., “affibodies” [287]), while others present sequences in loops (e.g., “knottins” [288] or “atrimers” [289], which can be modified subsequently by chemical means to increase their rigidity still further [290]. Aptamers have been
created to an enormous range of targets and a number are now on the market, either as
therapeutics [291] or diagnostic agents [292]. Their appearance is bound to increase rapidly,
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as they are highly biocompatible, can avoid being targets of the immune system, and can
be manufactured by standard means.
As drugs go, however, they are still quite large, in order for the scaffold to fulfil the
requirement for ease and reproducibility of folding. The composition of the structures
obtained is of necessity confined to amino acids, (although a limited range of non-natural
amino acids can be incorporated), and the initial discovery process, particularly for the
cell-free systems, requires prior knowledge of the target structure to which the aptamer
must bind.
Recently, however, a combinatorial amino acid structuring technology has been described that overcomes these limitations and that can take development of peptide aptamers
to the next stage. In this technique (termed Mozaic), combinatorial libraries are produced
by presenting mixtures of amino acids in a close-packed 2D mosaic array on the surface of
nanoparticles [293]. The nanoparticles are actually micelles and the amino acids are the
head-groups of the amphiphiles used to form the micelles, which form spontaneously when
the amphiphiles are dispersed in aqueous media. Starting with a pool of the 20 amino acids
(supplemented if desired by sugars, steroids, heterocyclics, and other non-natural amino
acid residues) a suspension of micelles can be prepared that contains a predetermined
selection from the starting pool, all mixed together in all possible random configurations
on the surface of those micelles. A whole library of micelles can be prepared in this way,
each with a slightly different combination of amino acid monomers.
Each member of the library can then be tested in a bioassay to determine which combination of amino acids is most effective at eliciting a certain desired behaviour. The micelles
are non-toxic and biocompatible, so are amenable to use in assays involving cell culture.
Because large amounts of the building blocks are readily synthesisable, micelles can be
produced in large enough quantities that they can bring about changes in the behaviour
of cells, rather than simply binding to them. Such changes can include cell differentiation, cytokine secretion, or induction of apoptosis. The process is iterative, so that after
one amphiphile combination has been identified as positive, modifications can be made
(e.g., reducing the number of components, or substituting them for others) to improve the
response still further.
Because the read-out is a change in cell behaviour, results can be obtained even in the
absence of knowledge as to what receptor needs to be targeted to achieve a desired effect
and indeed, the technique can be employed to discover new, hitherto unknown receptors
on cells whose stimulation can bring about the behaviour sought.
Under certain circumstances it is possible to test the activity of the micelles in in vivo
models for disease. Normally, however, because of the labile nature of micelles, it is not
possible to employ them directly as therapeutic agents, and their conversion to more
stable peptide aptamers, particularly planar ring structures mimicking the planar surface
of the micelle, gives rise to molecules that can change cell behaviour at very low concentrations [294]. Some of the most successful are cyclic peptides as small as 10 amino
acids (Figure 9), stabilised by cross-ring hydrogen bonds. Their potential in vivo has been
demonstrated in experimental models for rheumatoid arthritis [294].
7.4. Peptide-Based Vaccines
Short peptides play crucial roles in the immune system and are responsible for the
transmission of most of the immunological information [295]. The immune system does
not recognize an antigen per se, instead recognizing the B-cell, CD4+ (T-helper), and CD8+
(cytotoxic T lymphocyte, CTL) epitopes. B-cell epitopes (5–20 amino acids in length) are
conformational (e.g., helical) and, as the antibody binding site, they are critical in the
generation of humoral, antibody-based, immune responses. CD8+ epitopes (9–11 amino
acids) are non-conformational and are recognized by MHC-I cell receptors. They trigger
cellular immune responses and activate CTLs. CD4+ epitopes (typically 12–16 amino acids)
are recognized by MHC-II receptors in antigen presenting cells (APCs) and are responsible
for “help”; they further activate both humoral and cellular immune responses.
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L-alanine-D-isoglutamine) was approved as an adjuvant for a Leishmania animal vaccine [312]. Peptide-based vaccine approaches are relatively new and no peptide-based
vaccines are available on the market. However, a huge number of peptide-based vaccines—
targeting practically all possible infectious diseases, including acquired immune deficiency
syndrome (AIDS), malaria, and coronavirus disease 2019 (COVID-19)—are under development. Covaxx anti-COVID-19 peptide vaccine entered clinical trials and its UB-612 vaccine
will be tested in phase II/III clinical trials in Brazil [313]. The number of peptide-based
vaccines in clinical trials has grown significantly over the last decade; several of these,
particularly those against cancers, have reached phase III [314,315].
7.5. The Role of Short Peptides in Neurodegenerative Therapy
Short peptides are a vital and promising tool in the study of neurodegenerative
disorders (Alzheimer’s, Parkinson’s and Huntington’s diseases, amyotrophic lateral sclerosis, prion diseases). They can be used in either diagnosis or further treatment. As an
example, short peptide-based inhibitors of amyloid β aggregation in Alzheimer’s disease with reduced cytotoxicity are good drug candidates [32,33]. Notably, very short
peptides, like diphenylalanine and related compounds such as tert-butoxycarbonyl derivative (Table 2 [126]), are the core recognition motifs of β-amyloid polypeptides [98,126].
Fibrillar dynamic self-assembly behaviour of short peptides, leading to amyloid-like supramolecular structures, is a key insight into the nucleation, oligomerization, and the physical
properties of amyloid fibrils [126].
Table 2. Short peptides forming amyloid-like fibrils.
Name of Peptide

No. of Amino Acids

diphenylalanine
α,β-dehydrophenylalanine
Fmoc-diphenylalanine-konjac glucomannan
Ac-EFFAAE-NH2(AIP-1/2)
FFKLVFF
P11 (QQEFQWQFRQQ)

2
2
2
6
7
11

Theses very short peptides as well as cell-penetrating peptides are of relevance to
the highly efficient drug delivery systems (to target cells and subcellular organelles) and
the prevention of amyloid β aggreagation [316]. Interesting and promising aspects of
delivery strategy are peptide-based gel matrices to drug encapsulation [126]. Peptide-based
therapeutic drugs induce the neuronal growth, modulate neurogenesis [317], and finally
improve spatial memory. Their diversity prompts personalized therapies [40,318].
7.6. Immune Modulation Using Altered Peptide Ligands in Autoimmune Diseases
Altered peptide ligands (APL) refer to immunogenic peptides where the T cell receptor
(TCR) contact sites have been manipulated, resulting in altered T cell responses. As such,
1–3 amino acid mutations have been designed for immune modulation in autoimmune
diseases (Figure 10) [319]. Primary biliary cholangitis is a disease characterized by inflammatory destruction of small bile ducts in the liver leading to cirrhosis. Autoantibodies and
T cells are associated with primary biliary cholangitis. The E2 region of pyruvate dehydrogenase complexes 159–167 (PDC-E2) binds to HLA-A2, and substitutions of alanine at
position 5 of PDC-E2 peptide 159–167 leads to antagonism, by reducing peptide specific
effector functions of the CD8+ T cells [320]. Likewise, in myasthenia gravis, an autoimmune
disease regulated by CD4+ T-cells, which recognize the peptide epitopes p195–212 and
p259–271 of the human acetylcholine receptor alpha-subunit, single amino acid mutations
are able to inhibit myasthenia gravis autoimmune responses in mice. APL of these peptides
up-regulate tumor necrosis factor-beta and down-regulate interferon (IFN)-gamma and
IL-2 by the native peptide specific CD4+ T cells [321].
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pilloma virus containing part of the amino acid sequence (VHFFK) of MBP87–99 motif
(VHFFKNIVTPRTP) induced experimental autoimmune encephalitis in mice, however,
peptides from human papilloma virus type40 (VHFFR) and human papilloma virus type32
(VHFFH) prevented experimental autoimmune encephalitis [335]. Hence, microbial peptides, differing from the core motif of the self-MBP antigen, MBP87–99, may function as
natural APL in the modulation of autoimmune disease.
Dysregulated immune cells, in particular CD4+ T cells, are amongst the cause and
consequence of autoimmune diseases. Altering the fate of the auto-reactive CD4+ T cells
by either switching off pathogenic cells, or altering their cytokine profile from pro- to
anti-inflammatory is one mechanism of managing disease progression. The APL concept,
which can influence T cell activation and polarization, has shown promise in animal models
and in some human clinical trials as novel treatment modalities for auto immune diseases
in the future.
7.7. Relevance of Short Peptides in Stem Cell Research
Stem cell therapies are part of regenerative medicine aimed at improving the quality of
life through the fight with so far untreatable diseases. Short peptides are perfect candidates
for the development of 2D and 3D stem cell-culture materials due to their excellent opportunities. First of all, peptides mimic the protein functions. They inter alia interact with
DNA acting as regulatory factors. Oligopeptides imitate the extracellular matrix (the most
important part of the stem cell niche), which influences the fate of the stem cell [336,337].
Short peptides play an important role in the transmission of bio-information, modulation of
transcription, or restoration of genetically conditioned alterations being developed with
age [317,338]. In other words, they have geroprotective properties. The self-assembling
peptides in conjunction with stem cells are enable to regenerate damaged tissues [339].
They have relevance to the attenuation of the pathology of neurodegenerative diseases,
heart failures, or arthritis [339]. Short peptides are involved in the regulation of proliferation and differentiation of stem cells into individual cell-types [340]. Good examples
can be: Lys-Glu, Ala-Glu-Asp, Lys-Glu-Asp, Ala-Glu-Asp-Gly [317]. Modified peptides
(e.g., by mentioned earlier Fmoc moiety) enhance differentiation activity. Peptide-based
hydrogels are useful in controlling differentiation [341]. Very short peptides can penetrate
the epidermis sending signals to cells. Peptides related to stem cells show great potential
in the development of novel treatments, advance tissue regeneration, further rational
design of the extracellular matrix-materials (as stem cell culture substrates), and organ
engineering applications.
7.8. Short Peptide-Based Anti-Viral Agents against SARS-CoV-2
COVID-19 is an ongoing worldwide pandemic caused by SARS-CoV-2. So far, there are
no specific antiviral drugs available for the treatment of this disease. However, a large
number of small molecules displaying significant inhibitory activity against SARS-CoV-2
have been identified based on experimental and computational studies [342], among which
many are short peptides and peptide-like compounds.
Generally, the peptide-based SARS-CoV-2 inhibitors target two proteins, namely membrane (M) and spike (S) proteins [343]. The former plays a crucial role in facilitating virus
entry by mediating its interaction with the host cell receptor ACE2 and the latter (also called
3CLpro) is mainly in charge of the cleavage of viral polyproteins. Due to the high sequence
similarity of different CoV 3CLpros, some known peptide-based HIV protease inhibitors
have been used in clinical trials as the treatment of COVID-19, representative examples
including lopinavir (1) and ritonavir (2) (Figure 11) [344]. Besides, some de nova designed 3CLpro inhibitors have also been identified based on structure-based rational
design. For examples, Hilgenfeld and co-workers developed a series of α-ketoamide
derivatives (e.g., Figure 11(3,4)), which was proved to be potent inhibitor of the SARSCoV-2 3CLpro [345]; Liu, Jiang and co-workers discovered two peptidomimetic aldehydes
(Figure 11(5,6)), which showed excellent in vitro activity against SARS-CoV-2 3CLpro [346].
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Figure 11. Selected peptide-based anti-viral agents against SARS-CoV-2.

The protein-protein interaction of the S protein of SARS-COV-2 and the host cell receptor ACE2 has also been viewed as an ideal target for the development of anti-viral agents
against SARS-CoV-2. Particularly, the cryo-EM and co-crystal structures of the receptorbinding domain of SARS-CoV-2 with human ACE2 have been disclosed recently [349,350],
which paves the way to develop new entry inhibitors against SARS-COV-2. For example,
a 23-mer peptide sequence derived from human ACE2 was designed and synthesized
by Pentelute and co-workers, which can specifically bind to SARS-CoV-2-RBD with low
nanomolar affinity [351]. Besides, some potential ACE2-based peptide inhibitors have been
identified through computational approach and their efficacy needs to be further validated
in practice [352,353].
7.9. Antimicrobial Lactoferrin-Based Peptides as Anti-COVID-19
COVID-19 severity accrues due to its extremely high infection transmission rates [354].
Therefore, there is an urgent need for a novel, effective, and safe vaccine or drug to reduce
the viral transmission rate and thus suppress the infection.
Different types of vaccines against SARS-CoV-2 infection have been under preparation [355]. However, some challenges related to vaccine administration safety have been
of great concern. First, live or attenuated vaccines may recover their virulence leading
to a high risk of disease recurrence to the vaccinee. Furthermore, transient immunosuppression may be induced resulting in the vaccinees’ susceptibility towards infections [356].
Second, DNA vaccines may cause a mutation risk upon integration with the host genome.
Third, synthetic peptides are of low immunogenicity. Fourth, mRNA vaccines may need

Molecules 2021, 26, 430

26 of 45

further quality and safety evaluation to enter the pharmaceutical market. Finally, yet most
importantly, it was reported that vaccines produced from full-length spike (S) protein
against SARS-CoV-2 might be involved in liver damage [355]. Some studies reported that
sequenced strains of SARS-CoV-2 evolved into two subtypes (L and S), which showed
great variation in geographical distribution, transmission ability, and disease severity.
It is, then, speculated that the production of an efficient, safe, fully clinically approved
SARS-CoV-2 vaccine may not take less than many years. Besides, the probability of the
vaccines endorsement by the relevant authorities is considered low [355]. Many studies reported that Antimicrobial Peptides (AMPs), short sequence peptides polymer ranging from
10–100 amino acids, positively charged, amphiphilic, might be considered as a promising
solution to combat harmful microorganisms [357]. Lactoferrin (LF), as one of the AMPs,
is an iron-binding glycoprotein located at the mucosal layers of the human body. LF is
considered as the first line of defense against microbial infection, which may have the
potential to boost the innate immune response against COVID-19 [358]. Furthermore, LF is
a natural, safe, and effective antiviral drug, which is naturally produced, in human and
bovine milk, beside its anti-inflammatory and antitumoral properties. LF prevents the
viral infection by blocking the host cell receptors or binding to the virus particles [358].
Moreover, some studies showed that the usage of LF as an adjuvant to vaccines might
enhance their antiviral activity, beside being considered as a safe alternative to other used
adjuvants [358]. Therefore, it may be recommended to use the LF as an immunity booster
against SARS-CoV-2, rather than counting on the insufficiently tested vaccines, in order
to spare the required time for full testing and clinical approval of the required vaccine.
Finally, it may also be recommended to use LF in conjugation with the produced vaccine to
enhance its anti-COVID-19 activity.
7.10. Peptides from Digestion of Proteins
Food proteins are long-chain polymers of amino acids, encrypted into which are
peptides with potential health benefits, which may be used for the treatment and management of chronic and severe degenerative diseases such as hypertension, diabetes, obesity,
cancer, and metabolic disorders [359]. Bioactive peptides (BAP) from food proteins have
the amino acid structure and sequences similar to those that convey various signaling
mechanisms or hormones in our body. They are small molecular weight peptides usually
around 5 kDa. They have high tissue affinity, specificity, and efficiency to interact with
receptors, enzymes, and other biomolecules in the body to confer health promoting effects [360,361]. Some of these BAPs may be released in the gut when proteins are degraded
by the digestive enzymes such as pepsin, trypsin, chymotrypsin, and peptidases. However,
controlled enzymatic digestion of food proteins in vitro would release some of these BAPs,
which can be isolated and purified for therapeutic use.
The enzymatic production of bioactive peptides in vitro is greatly influenced by
factors such as the pH, degree of hydrolysis (DH), enzymes used, enzyme/substrate
ratio, temperature, hydrolysis time, and solvents used. It is well known that an abundance
of hydrophobic amino acids, such as Gly, Val, Ile, and Ala, in the peptide sequences
compared to the presence of other polar and charged amino acids, will contribute to the
high bioactivity observed [361].
Bioactive peptides are naturally formed by the exogenous protease enzymes produced
by microorganisms during fermentation. Some of the BAPs also have high antioxidant activities. Therefore, cultured milk products, fermented fruits and vegetables, and fermented
meat and fish products are considered beneficial adjuncts in human diets.
7.11. Nutraceuticals
At present people ingest foods not just to cover their nutritional necessities; they also
request healthy, natural, and convenient foods with biological activity. Interestingly,
some plant proteins encrypt diverse peptides with beneficial effects on health. The most
studied effects include anti-hypertensive, -cholesterolemic, -oxidant, -inflammatory, -cancer,
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-microbial, and immunomodulatory properties. Nowadays, different scientific areas
have focused their research on the functional properties of foods and food products.
Bioactive substances are known as components of foods that modulate metabolic processes, provide health benefits, and positive impact on the function of the body. A healthy
diet is a key factor to prevent some diseases [362,363]. The intake of proteins is essential for
maintaining a good health and it also provides bioactive peptides. Specific amino acids sequences encrypted in proteins in several foods have health effects, playing roles as fragment
of the whole protein (epitopes responsible for interactions between proteins and antibodies)
or being efficient after the release by proteolytic enzymes. Peptides with two or three
amino acids pass easily through the gastrointestinal tract to the blood. Proteins are a source
of bioactive di- and tri-peptides, among others, with certain biological activity [363–365].
Bioactive peptides have been known for several years and identified in plant and animal
sources and their interest has increased in the last decades. They comprise positive health
effects, i.e., on blood pressure and lipid metabolism, as well as analgesic, anti-thrombosis,
anti-atherosclerotic and opioid agents. Some peptides have more than one activity. They are
also useful to improve absorption of minerals [366–368]. Bioactive peptides are usually a
product of the hydrolysis by gastrointestinal digestive enzymes (pepsin, trypsin, and chymotrypsin), or by in vitro producers with specific enzymes, temperature, or pH. They may
contain hydrophobic amino acids in their sequences, a positive charge, and the resistance
to digestion by proteases and peptidases and a proline C terminal. Small peptides with
a dipeptide of proline-proline at their C terminal are more resistant to degradation by
proteases and peptidases of the stomach, pancreas, or intestine. Large peptides may be
active outside the intestinal epithelium. Recent studies of crop proteomic data revealed
that at least 6000 proteins may harbour bioactive peptides [368,369].
7.12. Marine Peptides
Marine bioactive peptides of diverse bioactivities, encompassing anti-inflammatory,
anticancer, and antioxidant activities, have been discovered from non-edible marine organisms and seafood processing by-products [370]. An interesting example is a hydrostatinSN1 (DEQHLETELHTHLTSVLTANGFQ), an anti-inflammatory peptide identified from
the venom gland of sea snake Hydrophis cyanocinctus [371], see Figure 12. In vivo
anti-inflammatory effects of the peptide have been demonstrated in murine models of
lipopolysaccharide (LPS)-induced acute lung injury [372] and in dextran sulfate sodiuminduced acute colitis [371]. Hydrostatin-SN1 suppressed LPS-induction of pro-inflammatory
cytokines, namely, tumor necrosis factor alpha (TNF-α), interleukin-6, and interleukin-1β,
in mice. In vivo evidence and study on LPS-treated RAW 264.7 cells indicated the possibility of hydrostatin-SN1 exerting its effect by interfering with the extracellular-signal
related kinase 1/2 and nuclear factor-κB (NF-κB) pathways [372]. In the murine colitis model, hydrostatin-SN1 exhibited its anti-inflammatory effect by binding to tumor
necrosis factor receptor 1 (TNFR1), hence disrupting the interaction between TNFR1 and
TNF-α. This, in turn, inhibited TNF-α-mediated activation of the NF-κB and mitogenactivated protein kinase proinflammatory pathways [371]. Hydrostatin-SN1 was proposed to be a promising candidate for the development of treatments for acute lung
injury [164] and inflammatory bowel diseases [371]. Bioactive peptides were also reported
from the giant barrel sponge, Xestospongia testudinaria [373] and rough leather coral,
Sarcophyton glaucum [374] KENPVLSLVNGMF derived from X. testudinaria was dosedependently cytotoxic to the human cervical cancer cell line (HeLa), being 3.8-fold stronger
than anticancer drug 5-fluorouracil. By contrast, the peptide showed only a marginal 5%
cytotoxicity to Hek293, a non-cancerous, human embryonic kidney cell line [374]. Likewise,
AGAPGG, AERQ, and RDTQ identified from S. glaucum were more cytotoxic to HeLa cells
than 5-fluorouracil, besides low toxicity to Hek293 cells [374]. Together, the aforementioned
findings point to the potential of the four peptides as candidates for future development
of anticancer drugs. Antioxidant peptides have been isolated from the by-products of the
fish, mollusk, and crustacean processing, e.g., fish scales, fish skin, squid skin, and abalone
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palmitoyl pentapetide-4 (matrixyl), palmitoyl tripeptide-1 (biopeptide CLTM), palmitoyl tripeptide5 (syn-coll), elaidyl-Lys-Phe-Lys-OH (lipospondin), hexapeptide-11 or pentamide-6, tripeptide10 citrulline (decorinyl) and neurotransmiter inhibitors [acetyl hexapeptide-3 (argireline),
pentapeptide-3 (vialox), pentapeptide-18 (leuphasyl), tripeptide-3 (syn-ake), acetyl octapeptide1/-3 (sNAP-8) peptides [382]. Moreover, several natural peptides, such as carnosine, keratin,
soybean, silk fibroin, and black rice peptides cannot be neglected [383]. These natural
peptides as cosmeceutical ingredients fit perfectly into the rules of sustainability due to
their high biodegadibility, low toxicity, moderate manufacturing costs, and convenient
scale-up production ability [382]. More specifically, the United Nation defined 17 Sustainable Development Goals for the better future of the world, in relation to either people or
the environment. In general, the main idea could be defined as “one global goal: good life
for all”. One of these 17 aims is “good health and well-being” [384]. The forecast for the
global cosmeceutical market predicts an increase by ~10% in the next years. Its significant
share will be related to peptide-based products.
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8. Conclusions and Future Outlook
Short peptides exhibit a remarkable array of biological functions, which may be used
by innovative therapies in almost all branches of medicine. They are synthesized and
investigated by research groups spread all over the world. The number of publications
and patents in the subject has been growing enormously over the last years. This global
review reflects this situation. It is written by scientists from all continents of the world
who tried to unveil “fifty shades” of short peptides with the emphasis on biomedical,
diagnostic, pharmaceutical, and cosmeceutical applications. In particular, peptides can
play either a leading role as drugs or a supporting role in diagnosis, treatment, cell penetration, or targeting, and many more. Peptide-based vaccines are an expected breakthrough
in cancer, microbial, or allergen immunotherapies. Natural and synthetic short peptides,
including peptidomimetics, find numerous applications in nanotechnology and are thoroughly investigated by structural bio-informatics and supramolecular chemistry. Moreover,
the development of comprehensive in silico techniques combined with efficient advanced
synthetic methods facilitates the production of peptide based chemical species of almost
unlimited applicabilities.
To sum up, short peptides can be a secret of idealized smart therapies.
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A
ACE(I)
AchRs
AIDS
Alloc
AMPs
APCs
APL
ARB
B
BAP
BOC
Bzl
CG
COVID-19
CPPs
CSD
CTL
2D
3D
DH
DKP
DNA
EDTA
FAS
FDA
FMOC
GALA
GAS
GDS
GFR
HeLa
HIV
HMG
HMGR
HOAt
HOBt
HPLC
IFN
IUPAC
LDL
LDLR
LF
LPS
LRPs
LRs
MBP
MD
MHC
NF
NLSs
NPC
PDC
PEG
PES
PPI

Acidic
angiotensin-converting enzyme (inhibitors)
acetylcholine receptors
acquired immune deficiency syndrome
allyloxycarbonyl
antimicrobial peptides
antigen presenting cells
altered peptide ligands
angiotensin receptor blockers
basic
bioactive peptides
butoxycarbonyl
benzyl
coarse grain
coronavirus disease 2019
cell penetrating peptides
Cambridge Structure Database
cytotoxic T lymphocyte
two-dimensional
three-dimensional
degree of hydrolysis
diketopiperazines
deoxyribonucleic acid
ethylenediaminetetraacetic acid
fatty acid synthase
Food and Drug Administration
fluorenylmethoxycarbonyl
glutamic acid–alanine–leucine–alanine
group A streptococcus
gene delivery system
growth factor receptors
human cervical cancer cell line
human immunodeficiency virus
high motility group
3-hydroxy-3-methylglutaryl CoA reductase
1-hydroxy-7-aza-benzotriazole
1-hydroxy-benzotriazole
high performance liquid chromatography
interferon
International Union of Pure and Applied Chemistry
low-density lipoprotein
LDL receptor
lactoferrin
lipopolysaccharide
low density lipoprotein receptors
leptin receptors
myelin basic protein
molecular dynamics
major histocompatibility complex
nuclear factor
nuclear localization signals
nuclear pore complex
pyruvate dehydrogenase complexes
polyethylene glycol
potential energy surface
proton-pump inhibitors
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RAS
RCSB PDB
RGD
RNA
SARS-COV-2
SPPS
SREBP2
SWOT
tBu
TFA
TFRs
TMC
TNF
TNFR

renin-angiotensin system
Research Collaboratory for Structural Bioinformatics Protein Data Bank
arginine–glycine–aspartic acid
ribonucleic acid
Severe Acute Respiratory Syndrome Coronavirus
solid-phase synthesis
sterol regulatory element-binding protein 2
strengths, weaknesses, opportunities, and threats
tert-butyl
trifluoroacetic acid
transferrin receptors
trimethyl chitosan
tumor necrosis factor alpha
tumor necrosis factor receptor 1
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